IP Library › Granted Patent US 7,442,308
Granted Patent B2
US 7,442,308 · App. 10/788,049 · Granted Oct 28, 2008

Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,442,308
App. No.
10/788,049
Filed
Feb 25, 2004
Granted
Oct 28, 2008
Kind
B2
Art Unit
1797
USPC
210/651
Abstract

A process for removing viruses in fibrinogen solutions and fibrinogen obtained thereof wherein the process starts with an adjusted purified fibrinogen solution, the adjusted purified solution is frozen and then thawed at a temperature between 5 and 20° C., the undissolved materials associated with the fibrinogen are subsequently separated, the temperature is adjusted and the resultant solution is finally subjected to nanofiltration using filters having a pore size smaller than 35 nm.

Claims (29)

1. A process for removing viruses in fibrinogen solutions for therapeutic application, comprising:

(a) obtaining a fibrinogen solution originating from previously purified human plasma, with a purity greater than or equal to 80% of fibrinogen with respect to the total proteins;

(b) stabilizing and freezing said fibrinogen solution and subsequent thawing thereof at a temperature between 5 and 20° C.;

(c) separating the undissolved materials;

(d) diluting the resultant protein solution; and

(e) nanofiltration of the diluted solution through a filter having a pore size smaller than 35 nm;

wherein the freezing, thawing and nanofiltration are carried out in the presence of at least one amino acid.

2. The process for removing viruses in. fibrinogen solutions for therapeutic application according to claim 1 , wherein the amino acid is arginine or glycine or combinations of the two.

3. The process for removing viruses in fibrinogen solutions for therapeutic application according to claim 1 , wherein the undissolved material is separated by a mesh filter after freezing and thawing.

4. The process for removing viruses in fibrinogen solutions. for therapeutic application according to claim 1 , wherein the undissolved material is separated by decanting after freezing and thawing.

5. The process for removing viruses in fibrinogen solutions for therapeutic application according to claim 1 , wherein the undissolved material is separated. by centrifuging after freezing and thawing,

6. The process for removing viruses in fibrinogen solutions for therapeutic application according to claim 1 , wherein the undissolved material is separated by direct filtration or by a gradient of filters after freezing and thawing.

7. The process for removing viruses in fibrinogen solutions for therapeutic application according to claim 1 , wherein the undissolved material is separated by a mesh filter, decanting, centrifuging, direct filtration, a gradient of filters, or combinations thereof, after freezing and thawing.

8. The process for removing viruses in fibrinogen solutions for therapeutic application according to claim 1 , wherein said resultant protein solution is diluted to a concentration less than or equal to 1.5 mg/ml of fibrinogen.

9. The process for removing viruses in fibrinogen solutions for therapeutic application according to claim 1 , wherein said diluted solution is adjusted to a temperature between 18 and 37° C. prior to nanofiltration.

10. The process for removing viruses in fibrinogen solutions for therapeutic application according to claim 1 , wherein said diluted solution is pre-filtered through filters having a pore size greater than or equal to 35 nm prior to nanofiltration.

11. The process for removing viruses in fibrinogen solutions for therapeutic application according to claim 1 , wherein the filter area for nanofiltration through a filter having a pore size smaller than 35 nm is between 10 and 1,000 cm 2 per liter of solution to be filtered.

12. The process for removing viruses in fibrinogen solutions for therapeutic application according to claim 1 , wherein the thawing temperature is between 8 and 13° C.

13. The process for removing viruses in fibrinogen solutions for therapeutic application according to claim 1 , wherein the amino acid concentration is greater than 0.1%.

14. The process for removing viruses in fibrinogen solutions for therapeutic application according to claim 13 , wherein the amino acid concentration is between 0.1 and 8%.

15. The process of claim 1 , wherein the filter has a pore size of 20 run or smaller.

16. A process for removing viruses in fibrinogen solutions for therapeutic application, comprising:

(a) obtaining a fibrinogen solution originating from previously purified human plasma, with a purity greater than or equal to 80% of fibrinogen with respect to the total proteins;

(b) stabilizing and freezing said fibrinogen solution and subsequent thawing thereof at a temperature between 5 and 20° C.;

(c) separating the undissolved materials;

(d) obtaining an arginine solution;

(e) diluting the resultant protein solution with the arginine solution;

(f) nanofiltering the diluted solution through a first filter having a pore size of 50 nm; and

(g) nanofiltering the diluted solution through a second filter having a pore size of 20 nm.